KARYOPHARM THERAPEUTICS INC - NOTE 3.000%10/1

Historical Portfolio Holders from Q4 2019 to Q3 2024

All holders as of September 30, 2024
Q3 2024
Type / Class
Debt / NOTE 3.000%10/1
Principal, excl. options Q3 2024
23.4M
Holdings value Q3 2024
$17.5M
Value change Q3 2024
+$1.52M
Grand Portfolio weight change Q3 2024
+0%
Number of holders
6
Number of buys Q3 2024
2
Number of sells Q3 2024
-1
Average buys Q3 2024 %
+0%
Average sells Q3 2024 %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Period Principal Value Change Price Investors
2024 Q3 $23.4M $17.5M +$1.52M $0.77 6
2024 Q2 $21.4M $13.7M -$77.8M $0.65 5
2024 Q1 $147M $90.6M -$11.7B $0.54 11
2023 Q4 $170M $86M +$11.4M $0.50 11
2023 Q3 $148M $107M $0 $0.62 11
2023 Q2 $148M $113M -$879K $0.68 11
2023 Q1 $177M $151M +$336K $0.77 11
2022 Q4 $157M $129M -$510K $0.76 9
2022 Q3 $91.4M $83.8M -$1.74M $0.81 8
2022 Q2 $101M $78.8M -$54.5M $0.73 10
2022 Q1 $161M $147M +$2.01M $0.84 17
2021 Q4 $158M $141M -$1.12M $0.82 18
2021 Q3 $161M $131M -$7.15M $0.75 16
2021 Q2 $161M $162M -$1.2M $1.00 16
2021 Q1 $162M $168M -$24.4M $1.04 13
2020 Q4 $179M $224M +$2.42M $1.26 13
2020 Q3 $177M $213M -$7.31M $1.20 13
2020 Q2 $180M $254M +$147K $1.40 16
2020 Q1 $179M $258M -$1.65M $1.44 14
2019 Q4 $180M $258M +$258M $1.43 15